Eilon D. Kirson is CSO at NovoCure Ltd (NVCR). They have made 11 open-market trades across 1 company since 2017, most recently 2019-02-27.
CIK 0001654356
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 11 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NVCR | 152,408 | $2.1M |
Shares reported on the most recent Form 4, priced at the 2019-03-01 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NVCR | SELL | 2019-01-16 | 2019-01-18 | $45.19 | $10.7M | +6.6% | +15.4% | -8.2% |
| NVCR | SELL | 2018-06-04 | 2018-06-06 | $28.89 | $20.0M | +1.3% | +4.4% | +42.2% |
| NVCR | SELL | 2018-04-18 | 2018-04-20 | $24.00 | $3.5M | +11.9% | +19.2% | +50.4% |
| NVCR | SELL | 2018-01-11 | 2018-01-16 | $22.00 | $557K | +13.4% | +1.4% | +3.4% |
| NVCR | SELL | 2017-11-06 | 2017-11-08 | $22.00 | $200K | -4.5% | +6.6% | +12.4% |
| NVCR | SELL | 2017-11-02 | 2017-11-06 | $22.00 | $75K | -13.1% | -6.5% | -0.5% |
| NVCR | SELL | 2017-10-31 | 2017-11-02 | $22.01 | $977K | -19.8% | -16.9% | +2.3% |
| NVCR | SELL | 2017-06-21 | 2017-06-22 | $16.78 | $2.2M | +4.9% | +9.8% | +21.7% |
| NVCR | SELL | 2017-06-19 | 2017-06-21 | $15.06 | $226K | +1.1% | +8.0% | +20.9% |
| NVCR | SELL | 2017-06-13 | 2017-06-15 | $15.01 | $272K | +14.2% | +23.1% | +47.5% |
| NVCR | SELL | 2017-06-09 | 2017-06-13 | $15.05 | $405K | +13.6% | +31.6% | +35.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.